Funapide

Funapide

Systematic (IUPAC) name
(7S)-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[6H-furo[2,3-f][1,3]benzodioxole-7,3'-indole]-2'-one
Clinical data
Routes of administration	Oral, topical
Identifiers
CAS Number	1259933-16-8
ATC code	None
PubChem	CID: 49836093
ChemSpider	34500834
Chemical data
Formula	C22H14F3NO5
Molecular mass	429.34547 g/mol
SMILES C1C2(C3=CC=CC=C3N(C2=O)CC4=CC=C(O4)C(F)(F)F)C5=CC6=C(C=C5O1)OCO6
InChI InChI=1S/C22H14F3NO5/c23-22(24,25)19-6-5-12(31-19)9-26-15-4-2-1-3-13(15)21(20(26)27)10-28-16-8-18-17(7-14(16)21)29-11-30-18/h1-8H,9-11H2/t21-/m0/s1 Key:NEBUOXBYNAHKFV-NRFANRHFSA-N

Funapide (INN) (former developmental code names TV-45070 and XEN402) is a novel analgesic under development by Xenon Pharmaceuticals in partnership with Teva Pharmaceutical Industries for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain. It acts as a small-molecule Na_v1.7 and Na_v1.8 voltage-gated sodium channel blocker. Funapide is being evaluated in humans in both oral and topical formulations, and as of July 2014, has reached phase IIb clinical trials.

See also

• Raxatrigine
• PF-05089771
• DSP-2230